Ignite Creation Date:
2024-05-05 @ 5:14 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00410345
Status:
COMPLETED
Last Update Posted:
2017-03-01
First Post:
2006-12-11
Brief Title:
Cervical Rippening With Antiprogesterone in Midtrimester Abortions
Sponsor:
Hadassah Medical Organization
Organization:
Hadassah Medical Organization
Study Overview
Official Title:
Cervical Rippening With Antiprogesterone in Midtrimester Abortions
Status:
COMPLETED
Status Verified Date:
2008-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Induction of midtrimester abortion includes cervical ripening and then contraction to induce uterine evacuation There are several protocols but most of them include using prostaglandins PG The disadvantages of using PG include uncomfortable side effects and limits of using it for women after cesarean section Mifepristone is an antiprogesterone drug and been used for induction of abortion in first and second trimesters abortions The aim of this study is to explore the effectiveness of Mifepristone for cervical ripening before high dose Oxytocin drip
Detailed Description:
The aim of this study is to explore the effectiveness of Mifepristone for cervical ripening before high dose Oxytocin drip in midtrimester abortions After informed consent all the women will be randomized for Mifepristone or placebo 48 hours later high dose oxytocin drip will be started and we will examine the success rate to induce abortion the duration from starting oxytocin till evacuation of uterus and side effects
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None